Tang Prize Honors CAR-T and TIL Therapy Pioneers, Spotlighting Cellular Immunotherapy Breakthroughs — The Tang Prize Foundation

Event summary

The Tang Prize in Biopharmaceutical Science awarded Drs. Steven A. Rosenberg, Michel Sadelain, and Carl H. June for pioneering CAR-T and TIL therapies.
CAR-T therapy has treated over 30,000 blood cancer patients since FDA approval in 2017.
TIL therapy has emerged as a new option for advanced solid tumors, particularly metastatic melanoma.
Recent advances in 2026 include CRISPR-Cas9-based cell engineering and applications in autoimmune diseases and cardiac repair.

The big picture

The Tang Prize recognition underscores the transformative impact of cellular immunotherapy, particularly CAR-T and TIL therapies, in treating blood cancers and solid tumors. These advancements represent a shift toward 'living drugs' that harness the immune system, positioning cellular therapies as a cornerstone of modern oncology. The expansion into new applications, such as CRISPR-based engineering and autoimmune disease treatment, signals a broader industry trend toward precision medicine and immune-based solutions.

What we're watching

Therapeutic Expansion: The pace at which CAR-T and TIL therapies expand into new indications, including solid tumors and autoimmune diseases, will determine their long-term market potential.
Regulatory Dynamics: How the FDA and other regulators adapt to emerging cellular therapies, particularly those involving CRISPR-Cas9, will shape the approval pathway for next-generation treatments.
Commercialization Challenges: Whether biopharma companies can sustain the high costs of manufacturing and delivering personalized cellular therapies at scale will impact profitability and accessibility.